A Phase 1/2 interventional study of VP-001 in Retinitis Pigmentosa 11, Retinal Degeneration and Retinal Disease, sponsored by PYC Therapeutics. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by PYC Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Retinal Dystrophies with a site in United States — 8 open to participants now, 16 under way, none of them phase 3. Retinal Dystrophies · United States.
Among the 27 studies in Retinal Dystrophies with a site in United States, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2025, is one of 6 in phase 1/2, reaches primary completion later than 13 of the 14 other live ones, and was the 25th registered.
60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.
Browse Retinal Dystrophies studies →8 of the 27 studies in Retinal Dystrophies with a site in United States are open now. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in United States, Australia, China
Ages 18–65
University of Rochester · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8
First in 1994; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is close to the median of 18 across 34 interventional studies indexed under Retinal Dystrophies.
Median enrollment 20 across the 16 interventional studies, 35 across the 11 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 27 have an industry lead sponsor. The 10 most frequent:
PYC Therapeutics is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
PYC Therapeutics has 4 studies filed under Retinal Dystrophies — fewer than ten, so there is no comparison to draw.
8 of the studies in Retinal Dystrophies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05294978Institute of Molecular and Clinical Ophthalmology BaselEyeConic: Qualification for Cone-Optogenetics | 2026-12 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
| NCT07502664Ray Therapeutics, Inc.Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) | 2027-02 |
| NCT05626920University of WashingtonDisulfiram for Treatment of Retinal Degeneration | 2027-02-01 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 27 studies in Retinal Dystrophies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2 repeat-dose, open-label, two-arm, parallel group safety and efficacy study of two doses of VP-001 (30 μg and 75 μg) in participants with confirmed PRPF31 mutation-associated retinal dystrophy, including participants previously treated with VP001 in the PLATYPUS Study or WALLABY Study for a minimum of 8 weeks.
60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.
This study's enrollment of 17 is close to the median of 18 across 34 interventional studies indexed under Retinal Dystrophies.
Browse Retinal Dystrophies studies →PYC Therapeutics is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Compared within Retinal Dystrophies, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Retinal Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
For participants not previously enrolled in VP001-CL101 or VP001-CL102 studies: Meet all of the following for visual function in the study eye at the Screening Visit:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VP-001
Drug: VP-001
VP-001 is an oligonucleotide-peptide conjugate administered intravitreally.
To determine the safety of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy.
The incidence, severity, and relatedness of ocular TEAEs and TE-SAEs in the study eye over a 26-month time period for each of the repeat doses
Time frame: 26 months
To determine the change from Baseline (Visit 2) through End of Study/Early Termination in BCVA letter score using ETDRS charts
To determine the efficacy of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy, RP11. A gain of Early Treatment Diabetic Retinopathy Study (ETDRS) letters in Best-Corrected Visual Acuity (BCVA) from Baseline through EOS/ET would indicate vision improvement.
Time frame: 24 months
To determine the change from baseline (Visit 2) through End of Study/Early Termination in Low Luminance Visual Acuity (LLVA) letter score
To determine the efficacy of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy, RP11.
Time frame: 24 months
Change from Baseline (Visit 2) through End of Study/Early Termination in visual field sensitivity, Mean deviation (Mean Defect) as measured by standard static perimetry (Humphries)
To determine the efficacy of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy, RP11.
Time frame: 24 months
Change from Baseline (Visit 2) through End of Study/Early Termination in mean retinal sensitivity
To determine the efficacy of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy, RP11. \> mean retinal sensitivity will be measured by fundus-guided microperimetry, measured in dB (Decibels).
Time frame: 24 months
Change from Baseline (Visit 2) through End of Study/Early Termination in preserved EZ area on SD-OCT
SD-OCT refers to Spectral Domain Optical Coherence Tomography. A preserved EZ area refers to the region of the retina where the Ellipsoid Zone (EZ), a distinct hyperreflective band representing the inner segments of photoreceptor cells, remains intact and visible, indicating relatively healthy photoreceptor function, often measured in a specific area on the scan to monitor disease progression in conditions like retinitis pigmentosa. To determine the efficacy of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy, RP11.
Time frame: 24 months
Change from Baseline (Visit 2) through End of Study/Early Termination in participant reported outcome measures utilizing the Michigan Retinal Degeneration Questionnaire (MRDQ)
The Michigan Retinal Degeneration Questionnaire (MRDQ) is a psychometrically validated patient reported outcomes (PRO) measure for patients with inherited retinal degenerations. This is to determine the efficacy of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy, RP11.
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Mar 2028, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VP-001
PYC Therapeutics